Prognostic factors associated with long-term survival and recurrence in pancreatic adenocarcinoma

Hepato-Gastroenterology

Volumn 60, Issue 121, 2013, Pages 358-362

  Lee, Sung Ryol ^a   Kim, Hyung Ook ^a   Son, Byung Ho ^a   Yoo, Chang Hak ^a   Shin, Jun Ho ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Overall survival; Pancreatic cancer; Prognostic factor

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; JAUNDICE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PERINEURAL INVASION; PREOPERATIVE COMPLICATION; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84877695565     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12727     Document Type: Article

References (28)

1. American Cancer Society Statistics: Cancer facts and figures. American Cancer Society 2000; 3-14.
2. Statistics and Information Department, Minister's Secretariat: Vital statistics of Japan, Tokyo, Ministry of Health and Welfare 1992; 272-287.
3. Cubilla A, Fortner JG, Fitzgerald P: Lymph node involvement in carcinoma the pancreas area. Cancer 1978; 41:880-887. (Pubitemid 8313223)
4. Birk D, Fortnagel G, Formentini A, et al.: Small carcinoma of the pancreas: factors of prognostic relevance. J. Hepatobiliary Surg 1998; 5:450-454. (Pubitemid 128662618)
5. Satake K, Nishiwaki H, Yokomatsu H, et al.: Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas. Surg Gynecol Obstet 1992; 175(3):259-265.
6. Nagakawa T, Kayahara M, Ohta T, et al.: Patterns of neural and plexus invasion of human pancreatic cancer and experimental cancer. Int J Pancreatol 1991; 10(2):113-119.
7. Ishikawa O, Ohigashi H, Sasaki Y, et al.: Practical usefulness of lymphatic and connective tissue clearance for carcinoma of the pancreas head. Ann Surg 1998; 208(2):215-220.
8. Jung KW, Park S, Kong HJ, et al.: Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci 2010; 25(8):1113-1121.
9. Jemal A, Siegel R, Xu J, et al.: Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5):277-300.
10. Wray CJ, Ahmad SA, Matthews JB, et al.: Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 2005; 128(6):1626-1641. (Pubitemid 40692556)
11. Smith RA, Dajani K, Dodd S, et al.: Preoperative resolution of jaundice following biliary stenting predicts more favorable early survival in resected pancreatic ductal adenocarcinoma. Ann Surg Oncol 2008; 15:3138-3146.
12. Konstantinidis IT, Deshpande V, Zheng H, et al.: Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma? J Gastrointest Surg 2010; 14(2):261-267.
13. Garcea G, Dennison AR, Ong SL, et al.: Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2007; 33(7):892-897. (Pubitemid 47279056)
14. Berger AC, Watson JC, Ross EA, et al.: The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004; 70(3):235-240.
15. Sierzega M, Popiela T, Kulig J., et al.: The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic cancer. Pancreas 2006; 33(3):240-245. (Pubitemid 44470138)
16. Bockman DE, Buchler M, Beger HG: Interaction of pancreatic ductal carcinoma with nerves leads to nerve damage. Gastroenterology 1994; 107(1):219-230. (Pubitemid 24195365)
17. Helm J, Centeno BA, Coppola D, et al.: Histological characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer. Cancer 2009; 115(18):4080-4089.
18. Scartozzi M, Galizia E, Verdecchia L, et al.: Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. Br J Cancer 2006; 95(4):445-449. (Pubitemid 44232552)
19. Cetintas SK, Kurt M, Ozkan L, et al.: Factors influencing axillary node metastasis in breast cancer. Tumori 2006; 92(5):416-422. (Pubitemid 44861778)
20. Van Roest MHG, Gouw ASH, Peeters PMJG, et al.: Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: perineural growth more important prognostic factor than tumour localization. Ann Surg 2008; 248(1):97-103.
21. Neoptolemos JP, Stocken DD, Dunn JA, et al.: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234(6):758-768. (Pubitemid 33117196)
22. Wasif N, Ko CY, Farrell J, et al.: Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol 2010; 17(9):2312-2320.
23. Geer RJ, Brennan MF: Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165(1):68-72.
24. Lim JE, Chien MW, Earle CC: Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237(1):74-85. (Pubitemid 36622320)
25. Berlin JD, Catalano P, Thomas JP, et al.: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20(15):3270-3275. (Pubitemid 34831525)
26. Herrmann R, Bodoky G, Ruhstaller T, et al.: Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25(16):2212-2217. (Pubitemid 46954645)
27. Oettle H, Richards D, Ramanathan RK, et al.: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16(10):1639-1645. (Pubitemid 41510138)
28. Louvet C, Labianca R, Hammel P, et al.: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and CISCAD phase III trial. J Clin Oncol 2005; 23(15):3509-3516.